Overview

Obinutuzumab in Treatment of Fibrillary Glomerulonephritis

Status:
RECRUITING
Trial end date:
2026-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this research is to learn if Obinutuzumab is effective and safe in treating patients with fibrillary glomerulonephritis (FGN).
Phase:
PHASE2
Details
Lead Sponsor:
Mayo Clinic
Treatments:
obinutuzumab